MA45150A - Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier - Google Patents

Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier

Info

Publication number
MA45150A
MA45150A MA045150A MA45150A MA45150A MA 45150 A MA45150 A MA 45150A MA 045150 A MA045150 A MA 045150A MA 45150 A MA45150 A MA 45150A MA 45150 A MA45150 A MA 45150A
Authority
MA
Morocco
Prior art keywords
adrenergic
beta
prevention
treatment
disorders associated
Prior art date
Application number
MA045150A
Other languages
English (en)
Inventor
Anthony C Blackburn
Quyen-Quyen Do
Maiko Nagura
Thuy-Anh Tran
Brett Ullman
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA45150A publication Critical patent/MA45150A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA045150A 2016-06-06 2017-06-05 Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier MA45150A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662346293P 2016-06-06 2016-06-06

Publications (1)

Publication Number Publication Date
MA45150A true MA45150A (fr) 2021-05-05

Family

ID=59067920

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44037A MA44037B1 (fr) 2016-06-06 2017-06-04 Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
MA045150A MA45150A (fr) 2016-06-06 2017-06-05 Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA44037A MA44037B1 (fr) 2016-06-06 2017-06-04 Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci

Country Status (29)

Country Link
US (5) US20190284200A1 (fr)
EP (1) EP3464292B8 (fr)
JP (3) JP6771246B2 (fr)
KR (2) KR102408272B1 (fr)
CN (1) CN109563103B (fr)
AR (1) AR108772A1 (fr)
AU (2) AU2017278102B2 (fr)
CA (1) CA3026024C (fr)
CL (1) CL2018003451A1 (fr)
CO (1) CO2019000041A2 (fr)
CR (1) CR20180595A (fr)
DK (1) DK3464292T3 (fr)
EA (1) EA201892817A1 (fr)
EC (1) ECSP19001018A (fr)
ES (1) ES2929737T3 (fr)
IL (2) IL289378B (fr)
MA (2) MA44037B1 (fr)
MX (2) MX387995B (fr)
MY (1) MY195982A (fr)
NI (1) NI201800130A (fr)
NZ (1) NZ749202A (fr)
PE (1) PE20190445A1 (fr)
PH (1) PH12018502550B1 (fr)
PT (1) PT3464292T (fr)
SG (1) SG11201810788QA (fr)
TN (1) TN2018000391A1 (fr)
TW (2) TWI752963B (fr)
UA (1) UA125120C2 (fr)
WO (1) WO2017214002A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
CN111699189B (zh) * 2017-12-06 2025-02-18 艾尼纳制药公司 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (fr) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activation de la pyruvate kinase r
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023017388A1 (fr) * 2021-08-09 2023-02-16 Arena Pharmaceuticals, Inc. Modulateurs du récepteur bêta-3 adrénergique utiles dans le traitement ou la prévention de l'insuffisance cardiaque
JP2024532227A (ja) * 2021-08-26 2024-09-05 アリーナ ファーマシューティカルズ， インコーポレイテッド 腎嚢胞性疾患および心腎症候群の処置または予防のためのベータ３アドレナリン作動性受容体のモジュレーター
EP4699606A3 (fr) * 2021-10-06 2026-03-25 Arena Pharmaceuticals, Inc. Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
JP2025506667A (ja) * 2022-02-14 2025-03-13 バイオジェン・エムエイ・インコーポレイテッド エモパミル結合タンパク質阻害剤及びその使用
CN114539103B (zh) * 2022-03-21 2023-04-07 佳木斯黑龙农药有限公司 2-二氟乙氧基-6-三氟甲基苯磺酰氯的合成方法
CN116178220A (zh) * 2022-12-13 2023-05-30 爱斯特（成都）生物制药股份有限公司 一种制备(2s)-2-[[3-(甲基磺酰基l)苯氧基]甲基]环氧乙烷的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3028340C2 (de) * 1980-07-25 1987-02-05 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Amino-desoxy-1.4;3.6-dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US5254595A (en) 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
FR2751646B1 (fr) 1996-07-23 1999-01-22 Sanofi Sa Phenoxypropanolamine a action antagoniste beta3-adrenergique
AU7738298A (en) 1996-12-19 1998-07-15 Agrevo Uk Limited Chromones useful as fungicides
FR2780057B1 (fr) * 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
AU2525801A (en) * 1999-12-17 2001-06-25 Sanofi-Synthelabo Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them
DE20204129U1 (de) 2002-03-15 2002-07-25 Wella Ag, 64295 Darmstadt Mittel zur Färbung von Keratinfasern mit Chinolinium-Farbstoffen
WO2005092860A1 (fr) * 2004-03-23 2005-10-06 Pfizer Limited Composes servant au traitement de maladies
JP2008521805A (ja) * 2004-11-30 2008-06-26 アーテシアン セラピューティクス， インコーポレイテッド β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物
US8697674B2 (en) 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
WO2008094507A2 (fr) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Nouveaux composés de fusion
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
US8722851B2 (en) 2007-11-02 2014-05-13 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
CA2779252C (fr) 2008-10-31 2015-05-05 Pain Therapeutics, Inc. Analgesique anti-inflammatoire se liant a la filamine a
US20100279997A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Analgesic that binds filamin a
EP2488177B1 (fr) 2008-10-31 2016-10-12 Pain Therapeutics, Inc. Anti-inflammatoire et analgésique se liant à la filamine a
WO2010058318A1 (fr) * 2008-11-21 2010-05-27 Pfizer Inc. 1-oxa-8-azaspiro[4.5]décane-8-carboxamides en tant qu'inhibiteurs de faah
US8785634B2 (en) * 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
CA2805427A1 (fr) * 2010-07-23 2012-01-26 Merck Sharp & Dohme Corp. NOUVEAUX AGONISTES DU RECEPTEUR ß3-ADRENERGIQUE DERIVES DE LA PYRROLIDINE
JP2012092038A (ja) 2010-10-26 2012-05-17 F Hoffmann La Roche Ag 糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤
EP2882428B1 (fr) 2012-07-13 2019-01-16 Pain Therapeutics, Inc. Méthode pour inhiber la phosphorylation de la protéine tau
EP2872899B1 (fr) 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Analyse de la maladie d'alzheimer chez un patient vivant
GB201405359D0 (en) 2014-03-25 2014-05-07 Univ Liverpool Synthetic process
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
CN111699189B (zh) * 2017-12-06 2025-02-18 艾尼纳制药公司 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂

Also Published As

Publication number Publication date
CO2019000041A2 (es) 2019-04-30
NZ749202A (en) 2022-07-01
SG11201810788QA (en) 2018-12-28
US10479797B2 (en) 2019-11-19
TN2018000391A1 (en) 2020-06-15
AU2021206809B2 (en) 2023-01-05
TW201803877A (zh) 2018-02-01
CA3026024C (fr) 2024-07-02
NI201800130A (es) 2019-06-13
US20190284200A1 (en) 2019-09-19
US20190292196A1 (en) 2019-09-26
US10927123B2 (en) 2021-02-23
EA201892817A1 (ru) 2019-06-28
CN109563103B (zh) 2022-05-27
JP2020203945A (ja) 2020-12-24
MY195982A (en) 2023-02-27
ECSP19001018A (es) 2019-02-28
DK3464292T3 (da) 2022-10-31
PT3464292T (pt) 2022-11-15
TWI784840B (zh) 2022-11-21
PH12018502550A1 (en) 2019-11-04
JP7083087B2 (ja) 2022-06-10
US20200270264A1 (en) 2020-08-27
IL289378B (en) 2022-09-01
KR102408272B1 (ko) 2022-06-10
CN109563103A (zh) 2019-04-02
MX2021014043A (es) 2022-02-21
AU2017278102A1 (en) 2019-01-17
US20210340154A1 (en) 2021-11-04
EP3464292B1 (fr) 2022-09-21
PH12018502550B1 (en) 2023-01-27
MX387995B (es) 2025-03-19
MX2018015124A (es) 2019-09-09
AU2021206809A1 (en) 2021-08-12
WO2017214002A1 (fr) 2017-12-14
ES2929737T3 (es) 2022-12-01
IL289378A (en) 2022-02-01
MA44037A1 (fr) 2019-05-31
JP7449329B2 (ja) 2024-03-13
UA125120C2 (uk) 2022-01-12
CA3026024A1 (fr) 2017-12-14
PE20190445A1 (es) 2019-03-29
CR20180595A (es) 2019-04-09
IL263148A (en) 2018-12-31
TWI752963B (zh) 2022-01-21
AR108772A1 (es) 2018-09-26
EP3464292B8 (fr) 2022-10-26
EP3464292A1 (fr) 2019-04-10
US10662200B2 (en) 2020-05-26
BR112018075201A2 (pt) 2019-03-19
JP6771246B2 (ja) 2020-10-21
AU2017278102B2 (en) 2021-04-29
KR20190026731A (ko) 2019-03-13
JP2019518079A (ja) 2019-06-27
JP2022089984A (ja) 2022-06-16
US11560386B2 (en) 2023-01-24
MA44037B1 (fr) 2020-03-31
IL263148B (en) 2022-02-01
CL2018003451A1 (es) 2019-02-22
US20190389875A1 (en) 2019-12-26
KR20220025128A (ko) 2022-03-03
TW202237619A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
MA46052A (fr) Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
EP3525735A4 (fr) Ultrasons thérapeutiques pour troubles oculaires
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP3465212A4 (fr) Régulation du microbiote intestinal pour le traitement de troubles neurodégénératifs
EP3410934A4 (fr) Procédé et appareil pour le traitement de troubles respiratoires
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3773543A4 (fr) Polythérapies pour le traitement de la sclérose latérale amyotrophique et de troubles apparentés
EP3139914C0 (fr) Composés pour traiter des maladies et des troubles ophtalmiques
EP3180022A4 (fr) Cassette d'expression améliorée pour le conditionnement et l'expression de variantes du facteur viii pour le traitement des troubles de l'hémostase
MA51075A (fr) Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
MA39753A (fr) Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
EP2807412A4 (fr) Procédés et systèmes de surveillance nerveuse pour le traitement de troubles pharyngés
EP3500267A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
EP3331527A4 (fr) Procédés de traitement de troubles du développement à l'aide de pipradrol
EP3432843A4 (fr) Vêtement de compression pour troubles neurologiques et circulatoires
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
EP3393496A4 (fr) Agoniste de glp-1r à action prolongée pour la thérapie de troubles neurologiques et neurodégénératifs
MA52778A (fr) Méthodes de traitement de troubles associés au récepteur s1p1
EP3442547A4 (fr) Thérapies à base de probiotiques pour troubles du développement et autres troubles neurologiques
EP2999444A4 (fr) Système thérapeutique transdermique pour dosage à libération prolongée de pramipexole dans le traitement de troubles neurologiques
EP3638316A4 (fr) Thérapie génique pour troubles oculaires
EP3606542A4 (fr) Protéines pour le traitement de troubles de la fonction barrière épithéliale
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques